1
|
Liang C, Huang C, Nong Z, Li S, Lin M, Qin Z. Correlation between ABCB1 and OLIG2 polymorphisms and the severity and prognosis of patients with cerebral infarction. Open Med (Wars) 2024; 19:20230841. [PMID: 38221931 PMCID: PMC10787307 DOI: 10.1515/med-2023-0841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 10/09/2023] [Accepted: 10/12/2023] [Indexed: 01/16/2024] Open
Abstract
This study investigated the relationship between ATP-binding cassette sub-family B member 1 (ABCB1) and OLIG2 single nucleotide polymorphism (SNP) and neurological injury severity and outcome in cerebral infarction (CI). The neurological injury severity of 298 CI patients was evaluated by the National Institutes of Health Stroke Scale. The prognosis of CI patients at 30 days after admission was evaluated by the modified Rankin Scale. And 322 healthy people were selected as the control group. The SNPs of the ABCB1 gene (rs1045642) and OLIG2 gene (rs1059004 and rs9653711) were detected by TaqMan probe PCR, and the distribution of SNPs genotype was analyzed. SNP rs9653711 was correlated with CI. Recessive models of rs1045642 and rs9653711 were correlated with CI. The genotypes of rs1045642 and rs9653711 and genetic models were associated with CI severity. rs1045642 had no correlation with CI prognosis, while rs9653711 had less correlation. The genotype distribution and recessive model were associated with CI prognosis. SNP rs1059004 was not associated with CI severity and prognosis. Alcohol consumption, hypertension, diabetes, hyperlipidemia, and high levels of homocysteine (HCY) were independent risk factors for CI, while hypertension, hyperlipidemia, and HCY were associated with poor prognosis of CI. ABCB1 rs1045642 and OLOG2 rs9653711 are associated with CI severity.
Collapse
Affiliation(s)
- ChaoYing Liang
- Department of Neurology, The First People’s Hospital of Qinzhou, Qinzhou City, Guangxi Zhuang Autonomous Region, 535099, China
| | - CuiYan Huang
- Department of Neurology, The First People’s Hospital of Qinzhou, Qinzhou City, Guangxi Zhuang Autonomous Region, 535099, China
| | - ZhenRu Nong
- Department of Neurology, The First People’s Hospital of Qinzhou, Qinzhou City, Guangxi Zhuang Autonomous Region, 535099, China
| | - SongLiang Li
- Department of Neurology, The First People’s Hospital of Qinzhou, Qinzhou City, Guangxi Zhuang Autonomous Region, 535099, China
| | - MinShi Lin
- Department of Neurology, The First People’s Hospital of Qinzhou, Qinzhou City, Guangxi Zhuang Autonomous Region, 535099, China
| | - ZuYe Qin
- Department of Neurology, The First People’s Hospital of Qinzhou, Qinzhou City, Guangxi Zhuang Autonomous Region, 535099, China
| |
Collapse
|
2
|
Zhang H, Jiang M, Hou H, Li Q. Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients. Exp Ther Med 2021; 22:819. [PMID: 34131442 PMCID: PMC8193215 DOI: 10.3892/etm.2021.10251] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 03/18/2021] [Indexed: 11/06/2022] Open
Abstract
To investigate the efficacy of simvastatin on carotid atherosclerotic plaque (CAP) and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients, 130 elderly patients with CAP were randomly divided into observation (n=65) and control groups (n=65). The control group was treated with 75 mg/day aspirin enteric-coated tablets, and the observation group was administered additional 20 mg/day simvastatin. Serum total cholesterol, triglyceride, and high- and low-density lipoprotein cholesterol levels (evaluated via the endpoint method) were determined in both groups. Furthermore, the length, thickness and number of CAPs was measured using color Doppler ultrasonography. In addition, levels of inflammatory biomarkers including high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide, D-dimer and fibrinogen, as well as change in microemboli count, were also compared After treatment, the observation group exhibited a significant reduction in size, thickness, and number of CAP and intima-media thickness compared with before treatment. However, no significant difference was found in the indicators of CAPs in the control group before and after treatment. The levels of total cholesterol, triglyceride, and low-density lipid cholesterol decreased, while high-density lipid cholesterol increased in the observation group after treatment, with notable changes in the observation group compared with in the control group. Overall response rate was higher in the observation group compared with the control group. TNF-α, IL-6, and hs-CRP levels in the observation group decreased after treatment compared with those before treatment and those in the control group. Furthermore, the rate of microemboli positivity was lower in the observation group than in the control group. Moreover, the overall incidence of acute cardiocerebrovascular events was lower in the observation group than in the control group. Therefore, it was demonstrated that simvastatin can reduce blood lipid levels, decrease the quantity and size of plaques, alleviate inflammatory response, reduce microemboli formation and reduce the risk of cardiocerebrovascular events in elderly patients with CAP.
Collapse
Affiliation(s)
- Huali Zhang
- Department of Geriatrics, Gansu Institute of Traditional Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu 730050, P.R. China
| | - Min Jiang
- Department of Nephropathy, People's Hospital of Wuwei, Wuwei, Gansu 733000, P.R. China
| | - Hong Hou
- ECG Room, Xi'an no. 3 Hospital, Xi'an, Shaanxi 710008, P.R. China
| | - Qin Li
- Department of Geriatrics, Baoji City People's Hospital, Baoji, Shaanxi 721000, P.R. China
| |
Collapse
|
3
|
Jin W, Wu W, Yang K, Shen F, Fu N, Feng Y, Fu Y. The Single Nucleotide Polymorphisms of Chromosome 9p21 and CD147 Were Relevant with the Carotid Plaque Risk in Acute Cerebral Infarction Patients Among Chinese Han Population. J Mol Neurosci 2020; 70:1282-1292. [DOI: 10.1007/s12031-020-01540-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Accepted: 11/13/2019] [Indexed: 12/28/2022]
|
4
|
Xu B, Wu C, Wu W, Tan Y, Sun N, Cui J, Lu S, Wang J, Cen S. Study of Serum CD147 Level in Patients with Transient Ischemic Attack and CD147 Expression in Atherosclerotic Plaque. J Cardiovasc Transl Res 2018; 11:285-291. [PMID: 30039437 DOI: 10.1007/s12265-018-9817-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 06/29/2018] [Indexed: 01/14/2023]
Abstract
There is growing evidence that highlighted the potential effects of CD147 in atherosclerosis, but the potential implication of CD147 in diagnosis and treatment of transient ischemic attack (TIA) and acute cerebral infarction (ACI) is still unclear. In this work, we investigated the serum level of CD147 in patients with TIA and ACI, and CD147 expression in atherosclerotic plaque. The result showed significantly increasing serum level of CD147 in patients with TIA and ACI, and increasing amount of CD147 in vulnerable plaque compared with that in migrating plaque. The serum level of CD147 was correlation with risk of stroke after an episode of TIA. These results together suggest a potential involvement of CD147 in the development and progression of TIA and ACI and CD147 as a potential biomarker for stroke prediction.
Collapse
Affiliation(s)
- Bin Xu
- Department of Neurology, Fuxing Hospital, Capital Medical University, Fu Xing Men Wai Avenue No. 20, XiCheng District, Beijing, 100038, People's Republic of China.
| | - Chan Wu
- Department of Neurology, Fuxing Hospital, Capital Medical University, Fu Xing Men Wai Avenue No. 20, XiCheng District, Beijing, 100038, People's Republic of China
| | - Wenqing Wu
- Di Tan Hospital, Capital Medical University, Beijing, 100015, China.
| | - Yanguo Tan
- Department of Neurology, Fuxing Hospital, Capital Medical University, Fu Xing Men Wai Avenue No. 20, XiCheng District, Beijing, 100038, People's Republic of China
| | - Nannan Sun
- Department of Neurology, Fuxing Hospital, Capital Medical University, Fu Xing Men Wai Avenue No. 20, XiCheng District, Beijing, 100038, People's Republic of China
| | - Jian Cui
- Department of Neurology, Fuxing Hospital, Capital Medical University, Fu Xing Men Wai Avenue No. 20, XiCheng District, Beijing, 100038, People's Republic of China
| | - Siyu Lu
- Department of Neurology, Fuxing Hospital, Capital Medical University, Fu Xing Men Wai Avenue No. 20, XiCheng District, Beijing, 100038, People's Republic of China
| | - Jing Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, 100050, China
| | - Shan Cen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, 100050, China.
| |
Collapse
|
5
|
Łacina P, Butrym A, Mazur G, Bogunia-Kubik K. BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients. Genes (Basel) 2018; 9:genes9050226. [PMID: 29695106 PMCID: PMC5977166 DOI: 10.3390/genes9050226] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 04/16/2018] [Accepted: 04/17/2018] [Indexed: 01/20/2023] Open
Abstract
Multiple myeloma (MM) is a haematologic malignancy characterized by the presence of atypical plasma cells. Basigin (BSG, CD147) controls lactate export through the monocarboxylic acid transporter 1 (MCT1, SLC16A1) and supports MM survival and proliferation. Additionally, BSG is implicated in response to treatment with immunomodulatory drugs (thalidomide and its derivatives). We investigated the role of single nucleotide polymorphisms (SNPs) in the gene coding for BSG and SLC16A1 in MM. Following an in silico analysis, eight SNPs (four in BSG and four in SLC16A1) predicted to have a functional effect were selected and analyzed in 135 MM patients and 135 healthy individuals. Alleles rs4919859 C, rs8637 G, and haplotype CG were associated with worse progression-free survival (p = 0.006, p = 0.017, p = 0.002, respectively), while rs7556664 A, rs7169 T and rs1049434 A (all in linkage disequilibrium (LD), r² > 0.98) were associated with better overall survival (p = 0.021). Similar relationships were observed in thalidomide-treated patients. Moreover, rs4919859 C, rs8637 G, rs8259 A and the CG haplotype were more common in patients in stages II⁻III of the International Staging System (p < 0.05), while rs8259 A correlated with higher levels of β-2-microglobulin and creatinine (p < 0.05). Taken together, our results show that BSG and SLC16A1 variants affect survival, and may play an important role in MM.
Collapse
Affiliation(s)
- Piotr Łacina
- Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland.
| | - Aleksandra Butrym
- Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wrocław, Poland.
| | - Grzegorz Mazur
- Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wrocław, Poland.
| | - Katarzyna Bogunia-Kubik
- Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland.
| |
Collapse
|
6
|
Popa-Wagner A, Glavan DG, Olaru A, Olaru DG, Margaritescu O, Tica O, Surugiu R, Sandu RE. Present Status and Future Challenges of New Therapeutic Targets in Preclinical Models of Stroke in Aged Animals with/without Comorbidities. Int J Mol Sci 2018; 19:ijms19020356. [PMID: 29370078 PMCID: PMC5855578 DOI: 10.3390/ijms19020356] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 01/18/2018] [Accepted: 01/22/2018] [Indexed: 01/02/2023] Open
Abstract
The aging process, comorbidities, and age-associated diseases are closely dependent on each other. Cerebral ischemia impacts a wide range of systems in an age-dependent manner. However, the aging process has many facets which are influenced by the genetic background and epigenetic or environmental factors, which can explain why some people age differently than others. Therefore, there is an urgent need to identify age-related changes in body functions or structures that increase the risk for stroke and which are associated with a poor outcome. Multimodal imaging, electrophysiology, cell biology, proteomics, and transcriptomics, offer a useful approach to link structural and functional changes in the aging brain, with or without comorbidities, to post-stroke rehabilitation. This can help us to improve our knowledge about senescence firstly, and in this context, aids in elucidating the pathophysiology of age-related diseases that allows us to develop therapeutic strategies or prevent diseases. These processes, including potential therapeutical interventions, need to be studied first in relevant preclinical models using aged animals, with and without comorbidities. Therefore, preclinical research on ischemic stroke should consider age as the most important risk factor for cerebral ischemia. Furthermore, the identification of effective therapeutic strategies, corroborated with successful translational studies, will have a dramatic impact on the lives of millions of people with cerebrovascular diseases.
Collapse
Affiliation(s)
- Aurel Popa-Wagner
- Griffith University School of Medicine, Gold Coast Campus, QLD, Queensland Eye Institute, Brisbane, QLD 4101, Australia.
- Department of Functional Sciences, Center of Clinical and Experimental Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
| | - Daniela-Gabriela Glavan
- Psychiatry Clinic Hospital, University of Medicine and Pharmacy of Craiova, Petru Rares Street 2, 200349 Craiova, Romania.
| | - Andrei Olaru
- Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
| | | | - Otilia Margaritescu
- Department of Neurosurgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
| | - Oana Tica
- Department of "Mother and Child", University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
| | - Roxana Surugiu
- Department of Functional Sciences, Center of Clinical and Experimental Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
| | - Raluca Elena Sandu
- Department of Functional Sciences, Center of Clinical and Experimental Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
| |
Collapse
|